4%/2% Cr/DOX showed decreased AST-to-ALT ratios, liver fibrosis biomarker expression, liver inflammation, oxidative stress when compared with the 2% Cr/DOX group, suggesting that a one-week Cr loading phase (i.e., high Cr intake) may be a better treatment option for enhancing liver function and decreasing the liver inflammation associated with DOX treatment. The gene discussed is GPT; the disease is digestive system neoplasm.